2. Search Result
Search Result
Results for "

AChE/BuChE inhibitor

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

5

Natural
Products

2

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0034S
    Donepezil-d5 hydrochloride

    E2020-d5

    		 Cholinesterase (ChE) Neurological Disease
    Donepezil-d5 (hydrochloride) is deuterium labeled Donepezil (Hydrochloride). Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE[1]. Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity[2].
    Donepezil-d5 hydrochloride
  • HY-B0034S1
    Donepezil-d4 hydrochloride

    E2020-d4

    		 Cholinesterase (ChE) Neurological Disease
    Donepezil-d4 (hydrochloride) is the deuterium labeled Donepezil hydrochloride. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE[1]. Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity[2].
    Donepezil-d4 hydrochloride
  • HY-150728
    AChE-IN-22

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-22 (compound 10q) is a selective acetylcholinesterase (AChE) inhibitor against AChE and BuChE with the IC50 values of 0.88 μM and 10 μM, respectively. AChE-IN-22 can bind to both the CAS (catalytic active site) and PAS (peripheral anionic site) of AChE and has the potential for the research of Alzheimer's disease .
    AChE-IN-22
  • HY-147939
    AChE/BuChE-IN-3

    		Cholinesterase (ChE) Amyloid-β Cancer
    AChE/BuChE-IN-3 is a potent and blood-brain barrier (BBB) penetrant AChE and BuChE dual inhibitor with IC50s of 0.65 μM and 5.77 μM for AChE and BuChE. AChE/BuChE-IN-3 also inhibits Aβ1-42 aggregation. AChE/BuChE-IN-3 has effectively neuroprotective activities and nearly no toxicity on SH-SY5Y cells. AChE/BuChE-IN-3 can be used for researching Alzheimer's disease .
    AChE/BuChE-IN-3
  • HY-144392
    AChE/BuChE-IN-1

    		Cholinesterase (ChE) Neurological Disease
    AChE/BuChE-IN-1 (Compound 1), a chrysin derivative, is a selective butyrylcholinesterase (BuChE) inhibitor with an IC50 of 0.48 μM. AChE/BuChE-IN-1 inhibits acetylcholinesterase (AChE) with an IC50 of 7.16 μM. AChE/BuChE-IN-1 shows strong scavenging ·OH activities with a IC50 of 0.1674 μM. AChE/BuChE-IN-1 inhibits reactive oxygen species (ROS), Aβ1-42 aggregation (self-, Cu2+-induced, AChE-induced). AChE/BuChE-IN-1 has high BBB permeability and bioavailability and low cell toxicity. AChE/BuChE-IN-1 has the potential for Alzheimer' disease (AD) research .
    AChE/BuChE-IN-1
  • HY-149090
    AChE/BuChE/MAO-B-IN-2

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent AChE/BuChE inhibitor and showed good blood brain barrier (BBB) permeability in vitro with an IC50 value of 5.3 μM, 12.4 μM, 1.9±0.08 μM, for AChE, BuChE, huMAO-B, respectively. AChE/BuChE/MAO-B-IN-2 (compound 4b) can inhibit excess AChE/BuChE in Alzheimer's disease (AD) brain. AChE/BuChE/MAO-B-IN-2 (compound 4b) can be used in anti-Alzheimer's research .
    AChE/BuChE/MAO-B-IN-2
  • HY-163537
    AChE/BuChE-IN-5

    		Cholinesterase (ChE) Neurological Disease
    AChE/BuChE-IN-5 (compound 5a) is a dual target inhibitor. AChE/BuChE-IN-5 has excellent nanomolar inhibitory activity on acetylcholinesterase (AChE) (IC50=46.9 nM) and butyryl cholinesterase (BuChE) (IC50=3.5 nM). AChE/BuChE-IN-5 can be used for Alzheimer's Disease research .
    AChE/BuChE-IN-5
  • HY-146142
    AChE/BuChE-IN-2

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE/BuChE-IN-2 (Compound 5f) is an orally active AChE and BuChE inhibitor with IC50 values of 0.72 μM and 0.16 μM, respectively. AChE/BuChE-IN-2 shows a non-competitive inhibition with AChE and shows potent self-induced β-amyloid (Aβ) aggregation inhibition with an IC50 of 62.52 μM. AChE/BuChE-IN-2 can cross the BBB .
    AChE/BuChE-IN-2
  • HY-170561
    AChE/BuChE-IN-6

    		Cholinesterase (ChE) Neurological Disease
    AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg/mL, respectively. AChE/BuChE-IN-6 also exhibits strong DPPH free radical scavenging activity (IC50 = 3.15 μg/mL). In vivo toxicity studies indicate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical markers compared to the control group after long-term administration, and no abnormalities were observed in liver and kidney tissues. AChE/BuChE-IN-6 holds promise for research into Alzheimer's disease .
    AChE/BuChE-IN-6
  • HY-168167
    BuChE-IN-14

    		Endogenous Metabolite Neurological Disease
    BuChE-IN-14 is a novel compound that selectively inhibits acetylcholinesterase (AChE) activity. BuChE-IN-14 showed a concentration-dependent inhibitory effect on AChE in rat brain in vitro experiments. BuChE-IN-14 can increase the extracellular acetylcholine (ACh) concentration in the rat hippocampus and striatum at a certain dose. BuChE-IN-14 may help improve memory impairment caused by cholinergic dysfunction .
    BuChE-IN-14
  • HY-B0034
    Donepezil Hydrochloride
    Maximum Cited Publications
    14 Publications Verification

    E2020

    		 Cholinesterase (ChE) Neurological Disease Cancer
    Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .
    Donepezil Hydrochloride
  • HY-151562
    AChE/BuChE/MAO-B-IN-1

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC50s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ1 and σ2 receptors with Ki values of 42.8 nM (human σ1 receptor) and 191 nM (rat σ2 receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research .
    AChE/BuChE/MAO-B-IN-1
  • HY-B0034R
    Donepezil (Hydrochloride) (Standard)

    		Cholinesterase (ChE) Neurological Disease Cancer
    Donepezil (Hydrochloride) (Standard) is the analytical standard of Donepezil (Hydrochloride). This product is intended for research and analytical applications. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC50 of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .
    Donepezil (Hydrochloride) (Standard)
  • HY-115650
    TAE-1

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    TAE-1 is a potent inhibitor of AChE and BuChE. TAE-1 also inhibits Aβ fibril formation and aggregation. TAE-1 can be used for the researches of Alzheimer's disease .
    TAE-1
  • HY-121072
    ASS234

    		Monoamine Oxidase Cholinesterase (ChE) Neurological Disease
    ASS234 is a potent monoamino oxidase (MAO) inhibitor with IC50s of 5.2 nM and 43 nM for MAO-A and MAO-B, respectively. ASS234 also inhibits AChE and BuChE with IC50s of 350 nM and 460 nM, respectively .
    ASS234
  • HY-155620
    PD10

    		Cholinesterase (ChE) Neurological Disease
    PD10 is an AChE and BuChE inhibitor (hAChE IC50: 0.56 μM; eeAChE IC50: 0.59 μM; eqBuChE IC50: 1.06 μM). PD10 can be used for research of Alzheimer’s disease .
    PD10
  • HY-147980
    Aβ-IN-5

    		Amyloid-β Cholinesterase (ChE) Neurological Disease
    Aβ-IN-5 (Compound e12) is an orally active Aβ aggregation inhibitor. Aβ-IN-5 also inhibits AChE and BuChE with IC50 values of 21.29 μM and 1.32 μM, respectively. Aβ-IN-5 shows excellent neuroprotective effects and low neurotoxicity .
    Aβ-IN-5
  • HY-155622
    PD25

    		Cholinesterase (ChE) Neurological Disease
    PD25 is an AChE and BuChE inhibitor (hAChE IC50: 1.58 μM; eeAChE IC50: 1.63 μM; eqBuChE IC50: 2.39 μM). PD25 also has antioxidant activity, and inhibits DPPH (IC50: 29.55 μM). PD25 can be used for research of Alzheimer’s disease .
    PD25
  • HY-155621
    PD24

    		Cholinesterase (ChE) Neurological Disease
    PD24 is an AChE and BuChE inhibitor (hAChE IC50: 1.72 μM; eeAChE IC50: 1.76 μM; eqBuChE IC50: 2.64 μM). PD24 also has antioxidant activity, and inhibits DPPH (IC50: 28.72 μM). PD24 can be used for research of Alzheimer’s disease .
    PD24
  • HY-N0749
    Jatrorrhizine

    		Cholinesterase (ChE) 5-HT Receptor Bacterial Neurological Disease
    Jatrorrhizine is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine is a potent and orally active inhibitor of AChE (IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .
    Jatrorrhizine
  • HY-N0740
    Jatrorrhizine chloride
    1 Publications Verification

    		 Cholinesterase (ChE) 5-HT Receptor Bacterial Neurological Disease Inflammation/Immunology
    Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .
    Jatrorrhizine chloride
  • HY-N0749A
    Jatrorrhizine hydroxide
    1 Publications Verification

    		 Cholinesterase (ChE) 5-HT Receptor Bacterial Neurological Disease Inflammation/Immunology
    Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine hydroxide is a potent and orally active inhibitor of AChE (IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine hydroxide reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .
    Jatrorrhizine hydroxide
  • HY-150003
    Aβ1–42 aggregation inhibitor 1

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC50 value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .
    Aβ1–42 aggregation inhibitor 1
  • HY-N0740R
    Jatrorrhizine chloride (Standard)

    		Cholinesterase (ChE) 5-HT Receptor Bacterial Neurological Disease Inflammation/Immunology
    Jatrorrhizine (chloride) (Standard) is the analytical standard of Jatrorrhizine (chloride). This product is intended for research and analytical applications. Jatrorrhizine chloride is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of AChE (IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .
    Jatrorrhizine chloride (Standard)
  • HY-N11997
    Feralolide

    		Cholinesterase (ChE) Neurological Disease
    Feralolide is a dihydroisocoumarin isolated from the methanolic extract of aloe vera resin. Feralolide is also a dual inhibitor of AChE and BuChE, with IC50s of 55 μg/mL and 52 μg/mL respectively. Feralolide has antioxidant activity and inhibits 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2, 2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS). Feralolide could be used in research into cognitive disorders such as Alzheimer's disease, potentially restoring and enhancing memory .
    Feralolide
  • HY-155085
    hAChE-IN-3

    		Monoamine Oxidase Amyloid-β Cholinesterase (ChE) Neurological Disease
    hAChE-IN-3 (compounds 5c) is a potent and blood-brain barrier permeable AChE, BuChE， MAO-B-IN-1 and BACE-1 inhibitor, with IC50 values of 0.44, 0.08, 5.15 and 0.38 μM, respectively. hAChE-IN-3 has antioxidant activity and metal chelating ability. In addition, hAChE-IN-3 can bind to peripheral anion sites, and affect β amyloid and reduce Alzheimer's-associated neurodegeneration. hAChE-IN-3 has the potential for the research of Alzheimer's disease .
    hAChE-IN-3
  • HY-144388
    ChE/Aβ1-42-IN-1

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    ChE/Aβ1-42-IN-1 (compound 28) is a potent ChE and Aβ1-42 aggregation inhibitor with IC50s of 0.062, 0.767 and 1.227 µM for AChE, BuChE and Aβ1-42 aggregation, respectively. ChE/β1-42-IN-1 shows excellent BBB penetration. ChE/Aβ1-42-IN-1 is a potent multi-targeted anti-Alzheimer's agent .
    ChE/Aβ1-42-IN-1
  • HY-W027553
    Ipidacrine

    NIK-247 free base

    		 Cholinesterase (ChE) Potassium Channel Sodium Channel Neurological Disease Metabolic Disease
    Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC50 values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K + and Na +-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .
    Ipidacrine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: